579P A multicenter evaluation of a low pass whole genome sequencing-based solution for homologous recombination deficiency detection
A. Buisson(Centre Léon Bérard), I. Ray-Coquard(Centre Léon Bérard), P-A. Just(Hôpital Cochin), Trine Juhler‐Nøttrup(Copenhagen University Hospital), C. Montoto Grillot(Centre de Recherche en Cancérologie de Lyon), Andrew Martin(Clinica Universidad de Navarra), N. Colombo(European Institute of Oncology), M. Barberis(European Institute of Oncology), C. Roma(Fondazione IRCCS Istituto Nazionale dei Tumori), Pauline Gilson(Centre National de la Recherche Scientifique), D. Varcica(European Institute of Oncology), Pierre Saintigny(Université Claude Bernard Lyon 1), Francesca Bergantino(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Éric Pujade-Lauraine(KU Leuven), P Harter(Kliniken Essen-Mitte), Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Kohei Fujiwara(Keio University), Christian Schauer(Hospital of the Brothers of St. John of God), I. Vergote(Universitair Ziekenhuis Leuven), Alexandre Harlé(Centre National de la Recherche Scientifique)
Cited by 1
Related Papers
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|1.1k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412